Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTFields + Gemcitabine and Albumin-bound Paclitaxel in Locally Advanced Pancreatic Cancer
NCT05653453Phase 3Recruiting
- Sponsor
- Jiangsu Healthy Life Innovation Medical Technology
- Start
- Dec 2022
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Jiangsu Healthy Life Innovation Medical Technology. Primary endpoint: Overall Survival. Started Dec 2022; status: recruiting.
Beyond the preview
Go deeper on NCT05653453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05653453.